Summer Symposium 2015

CANCER COMPLEXITY:
Heterogeneity in Tumor Progression and Drug Response

Friday, June 12, 2015
8:30 a.m.-4:30 p.m.
MIT Johnson Athletics Center (Building 34)

Symposium

Registration

  • General registration (including industry/academic professionals, non-MIT students and postdocs, MIT and KI alumni)
  • MIT registration (current MIT faculty, students, postdocs, and staff; MIT email address required

The Koch Institute’s 14th annual Summer Symposium will explore the genetic and epigenetic heterogeneity within tumors that yields diverse cancer phenotypes, such as drug resistance. Speakers will highlight the latest breakthroughs in overcoming clinical challenges in cancer diagnostics and therapy. Come join us as we assemble cancer’s complex puzzle.

Speakers

Hemann

The Tumor Microenvironment Drives Heterogeneity in Therapeutic Response

Michael Hemann, PhD
Symposium Chair
Associate Professor of Biology
Koch Institute at MIT

Iacobuzio-Donahue

Genetic Features of Subclonal Evolution in Pancreatic Cancer

Christine A. Iacobuzio-Donahue, MD, PhD
Associate Director for Translational Research, David M. Rubenstein Center for Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center 

Jacks

Engineering the Cancer Genome

Tyler Jacks, PhD
Director
David H. Koch Professor of Biology
Koch Institute at MIT 

Nolan

The Deeper Phenotypes of the Single Cell in Cancer and Immunity

Garry P. Nolan, PhD
Rachford and Carlota Harris Professor, Department of Microbiology & Immunology
Stanford University School of Medicine 

Pe'er

Navigating the Phenotypic Landscape of Tumor Heterogeneity at Single-Cell Resolution

Dana Pe'er, PhD
Associate Professor of Biology and Systems Biology
Columbia University 

Polyak

Breast Tumor Evolution

Kornelia Polyak, MD, PhD
Professor, Department of Medicine, Harvard Medicial School
Department of Medical Oncology, Dana-Farber Cancer Institute 

Shaw

Tumor Heterogeneity and Drug Resistance

Alice Shaw, MD, PhD
Associate Professor, Department of Medicine, Harvard Medical School
Thoracic Cancer Program, Massachusetts General Hospital 

Stegmaier

Pediatric Cancer and Genome Simplicity

Kimberly Stegmaier, MD
Co-Director, Pediatric Hematologic Maligancy Program, Dana-Farber Cancer Institute & Boston Children's Hospital
Associate Professor of Pediatrics, Harvard Medical School 

Stegmeier

High Complexity Barcoding to Study Clonal Dynamics in Response to Cancer Therapy

Frank Stegmeier, PhD
Director
Novartis Institutes for Biomedical Research

Stratton

Signatures of Mutational Processes in Human Cancer

Sir Michael Stratton, PhD
Director
Wellcome Trust Sanger Institute

Swanton

Spatial and Temporal Dynamics of Tumour Evolution: Implications for Drug Development

Charles Swanton, MD, PhD
Professor
Francis Crick Institute and UCL Cancer Institute and Hospitals, UK